Oncotarget is a digital journal that researches on tumor and explores all its treatment possibilities. It is due to the increased complexity of cancer cases that led to the founding of this online print platform. The title “Oncotarget” is synonymous to molecular and cellular activities that are related to cancer, aging, nerve degeneration and microbes. The paper focusses on tracking the effect of treatment programs and newly discovered therapeutic procedures and protocols in assisting patients lead quality lifestyles that are satisfactory.
Further, the publishing pays a lot of attention on researching the evidences of relatively new and existing therapies, and how they impact a patient’s health. Of importance is that the paper explains the employment of these treatment protocols and their likelihood to be adopted in professional health care industry.
The journal’s reputation comes as a result of maximizing the impact of research by allowing peer reviews that provide authors with extensive, timely, and informative information that expands the outcome of their research efforts. Without being left out, the members comprising the editorial team have made major contributions to the paper. In fact, four authors of the paper have been recipient of the coveted Breakthrough Prize since 2013, the biggest recognition one can receive in health research fields. Visit classroomvoices.org to read more about Mikhail.
Our Mission and Vision
The free access online journal strives to avail the findings of scientific researches on timely basis for a global audience. Moreover, it tries to unveil the impact of surveys through informative and insightful peer reviews from other professional medical publishers. Through this paper, readers are able to get outstanding discoveries very quickly without any barriers of specialties. This, in the long term, nurtures the applications of basic and newly founded medical science in the eradication of chronic ailments.
About Dr. Mikhail Blagosklonny
He is a holder of a Doctorate Degree and a qualified Medical Doctor. Additionally, he is a professor in Roswell Park Cancer Institute in Buffalo, New York. Further, Dr. Mikhail Blagosklonny is a member of Oncotarget’s editorial team and a prolific contributor to many articles in the journal. As a matter of fact, he has had a role in over 250 publishing on review-related journals. He has also been a consulting editor of many informative articles that focus on improvement of protocols in cancer treatment. View Mikhail’s profile on Google Scholar